Welcome to our dedicated page for Climb Bio SEC filings (Ticker: CLYM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Climb Bio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Climb Bio's regulatory disclosures and financial reporting.
Climb Bio, Inc. will hold its 2026 annual stockholder meeting virtually on June 5, 2026 at 9:00 a.m. Eastern via www.proxydocs.com/CLYM, with a record date of April 7, 2026.
Stockholders will vote on electing two Class II directors, ratifying PricewaterhouseCoopers LLP as auditor for 2026, amending the certificate of incorporation to change how directors may be removed for cause, and amending the 2021 Equity Incentive Plan so its automatic share pool increase includes prefunded warrants. The company describes its classified board, committee structure, independence determinations, insider-trading and clawback policies, and executive compensation. In 2025, the CEO earned a $669,500 salary and $2.92 million in total compensation, and the auditor billed $686,400 in fees. A quorum requires a majority of outstanding common shares, noted as approximately 47,768,543 shares.
Climb Bio, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders, to be held virtually on June 5, 2026. Stockholders will vote on the election of two Class II directors, ratification of PricewaterhouseCoopers LLP as auditor, an amendment to the charter regarding removal for “cause,” and an amendment to the 2021 Equity Incentive Plan to include prefunded warrants in the automatic annual share-pool increase. The record date for voting is April 7, 2026, with approximately 47,768,543 shares outstanding as of that date. The proxy statement is marked preliminary — subject to completion and materials (including the 2025 Annual Report and Form 10-K) are available online.
Climb Bio, Inc. reported that Senior Vice President, Finance and principal accounting officer Cindy Driscoll will separate from the company by mutual agreement, effective April 30, 2026. This creates a leadership change in the finance organization.
Chief Financial Officer Dr. Susan Altschuller, who has served as CFO since October 2025, will also become the company’s principal accounting officer as of the separation date. The company highlights her extensive prior CFO and financial leadership roles in several biopharmaceutical companies and notes that her existing compensation arrangements remain unchanged. The filing also states that she has no disclosable related-party transactions or family relationships with directors or officers.
Climb Bio, Inc. is a clinical-stage biotechnology company focused on immune-mediated diseases. Its lead antibody, budoprutug, targets CD19 to deplete pathogenic B cells in primary membranous nephropathy (pMN), immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE). Budoprutug has orphan-drug designation for pMN, encouraging Phase 1b data in pMN, and multiple ongoing Phase 1/2 trials in pMN, ITP and SLE, including an intravenous and a high‑concentration subcutaneous formulation.
The company’s second program, CLYM116, is a next-generation anti‑APRIL ‘sweeper’ antibody aimed at IgA nephropathy and other B‑cell–mediated diseases. Early preclinical work suggests deep and durable APRIL and IgA suppression, and Phase 1 trials in healthy volunteers and parallel studies with partner Mabworks in China are underway. Climb Bio estimates its targeted indications encompass more than 500,000 U.S. patients, with broader potential across roughly 2 million people living with immune‑mediated diseases.
Climb Bio, Inc. reported fourth quarter and full-year 2025 results showing continued investment in its immune-mediated disease pipeline and a stronger balance sheet. Cash, cash equivalents and marketable securities were $160.7 million as of December 31, 2025, which the company expects will fund operations into 2028.
Full-year 2025 research and development expenses rose to $46.7 million from $14.3 million, while general and administrative expenses increased to $21.2 million from $16.0 million, reflecting pipeline and corporate growth. Net loss narrowed to $59.9 million in 2025 from $73.9 million in 2024, with loss per share improving to $0.88 from $1.53.
The company highlighted progress in multiple clinical programs. Budoprutug is in ongoing trials for primary membranous nephropathy, immune thrombocytopenia and systemic lupus erythematosus, plus a completed Phase 1 study of a subcutaneous formulation, with initial data from several studies expected in 2026. CLYM116 is in a Phase 1 healthy volunteer study, supported by a partner-led Phase 1/2 trial in IgA nephropathy.
Climb Bio, Inc. director Thomas Stephen Basil reported selling a total of 50,000 shares of Common Stock in open-market transactions under a pre-arranged Rule 10b5-1 trading plan. On February 25, 2026, he sold 33,687 shares at a weighted average price of $7.0046 per share, followed by 16,313 shares on February 26, 2026 at a weighted average price of $7.0060 per share. The filing notes that each day’s sales occurred in multiple trades within price ranges from $7.0000 to $7.0600 and from $7.0000 to $7.0400, respectively. After these transactions, Basil directly owned 154,657 shares.
Form 144 filing reporting a proposed sale of 50,000 common shares by a broker-dealer on 02/25/2026. The filing lists prior 10b5-1 sales by Stephen Thomas of 10,000 shares on 02/13/2026 for $58,141 and 90,000 shares on 02/12/2026 for $470,984. The securities are listed as common shares on NASDAQ.
BioImpact LLC filed a Schedule 13G reporting a significant passive stake in Climb Bio, Inc.. BioImpact beneficially owns 2,671,480 shares of Climb Bio common stock, representing 5.6% of the class as of 12/31/2025.
BioImpact has sole power to vote and dispose of all reported shares, with no shared voting or dispositive power. The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Climb Bio.
Climb Bio, Inc. director Thomas Stephen Basil reported selling a total of 100,000 shares of common stock in open-market transactions on February 12 and 13, 2026. He sold 90,000 shares at a weighted average price of $5.2332 on February 12 and 10,000 shares at a weighted average price of $5.8141 on February 13.
After these sales, Basil directly beneficially owns 204,657 shares of Climb Bio common stock. The filing states the trades were made under a Rule 10b5-1 trading plan adopted on October 14, 2025, and notes that each reported price reflects a weighted average of multiple individual trades within the disclosed price ranges.
The holder of CLYM common stock has filed a notice of proposed sale of 100,000 shares through Morgan Stanley Smith Barney on or after February 12, 2026 on NASDAQ, with an aggregate market value of $556,000. The filing states that 68,184,435 shares of this class were outstanding at the time of the notice.
The shares to be sold were acquired from the issuer as restricted stock units on January 1, 2025 (50,188 shares) and as founders’ shares on November 15, 2023 (49,812 shares). The seller represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.